EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Quantitative systems pharmacology modeling of macrophage‐targeted therapy combined with PD‐L1 inhibition in advanced NSCLC

Hanwen Wang iD, Theinmozhi Arulraj iD, Samira Anbari iD, Aleksander S Popel iD

Clinical and Translational Science · 2024

DOI: 10.1111/cts.13811 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Hanwen Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immune Checkpoint Inhibitors, B7-H1 Antigen. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors remained the standard‐of‐care treatment for advanced non‐small cell lung cancer (NSCLC) for the past decade. In unselected patients, anti‐PD‐(L)1 monotherapy achieved an overall response rate of about 20%. In this analysis, we developed a pharmacokinetic and pharmacodynamic module for our previously calibrated quantitative systems pharmacology model (QSP) to simulate the effectiveness of macrophage‐targeted therapies in combination with PD‐L1 inhibition in advanced NSCLC. By conducting in silico clinical trials, the model confirmed that anti‐CD47 treatment is not an optimal option of second‐ and later‐line treatment for advanced NSCLC resistant to PD‐(L)1 blockade. Furthermore, the model predicted that inhibition of macrophage recruitment, such as using CCR2 inhibitors, can potentially improve tumor size reduction when combined with anti‐PD‐(L)1 therapy, especially in patients who are likely to respond to anti‐PD‐(L)1 monotherapy and those with a high level of tumor‐associated macrophages. Here, we demonstrate the application of the QSP platform on predicting the effectiveness of novel drug combinations involving immune checkpoint inhibitors based on preclinical or early‐stage clinical trial data.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsImmune Checkpoint InhibitorsB7-H1 AntigenHumansAntineoplastic Combined Chemotherapy ProtocolsCD47 AntigenMacrophagesReceptors, CCR2Network PharmacologyComputer SimulationModels, BiologicalTumor-Associated Macrophages

Substanzen

Immune Checkpoint InhibitorsB7-H1 AntigenCD274 protein, humanCD47 AntigenReceptors, CCR2CD47 protein, humanCCR2 protein, human

Autor:innen und Institutionen

  • Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

ORCID-Profile: Hanwen Wang, Theinmozhi Arulraj, Samira Anbari, Aleksander S Popel

Förderung

  • NCI NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Wang, H., Arulraj, T., Anbari, S., & Popel, A. S. (2024). Quantitative systems pharmacology modeling of macrophage‐targeted therapy combined with PD‐L1 inhibition in advanced NSCLC. Clinical and Translational Science. https://doi.org/10.1111/cts.13811

Vancouver

Wang H, Arulraj T, Anbari S, Popel AS. Quantitative systems pharmacology modeling of macrophage‐targeted therapy combined with PD‐L1 inhibition in advanced NSCLC. Clinical and Translational Science. 2024. doi:10.1111/cts.13811

BibTeX
@article{Wang2024,
  author = {Wang, Hanwen and Arulraj, Theinmozhi and Anbari, Samira and Popel, Aleksander S},
  title = {Quantitative systems pharmacology modeling of macrophage‐targeted therapy combined with PD‐L1 inhibition in advanced NSCLC},
  journal = {Clinical and Translational Science},
  year = {2024},
  doi = {10.1111/cts.13811}
}
Kostenlos starten →